In 2007, FDA approved a rapamycin analogue for _____, due to its, ___.
A) Cancer treatment, antiproliferative properties
B) Diabetes treatment, insulin regulation
C) Heart disease treatment, lipid-lowering effects
D) Antibiotic use, antibacterial properties